Home | Contact |
( View All )
5/15/12 - Galectin Therapeutics Announces Initiation of Phase 1/2 Trial of Novel Combination Therapy for Advanced Metastatic Melanoma
5/11/12 - Galectin Therapeutics Announces First Quarter 2012 Financial Results
5/1/12 - Galectin Therapeutics Announces Long-term Engagement of Dr. Scott Friedman to Advise on Liver Fibrosis Programs
View the BIO CEO & Investor Presentation
Read Galectin’s shareholder letter
View the poster presented at EASL
(